articleJournal of Clinical OncologyFeb 2, 2022GREEN OA

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

DRDavid R. SpigelCFCorinne Faivre-FinnJEJhanelle E. GrayDVDavid VicenteDPDavid Planchard

Sarah Cannon · Tennessee Oncology · +31 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; P < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned. METHODS Patients with WHO performance…

Citation impact

1,267
total citations
FWCI
170.13
Percentile
100%
References
24
Citations per year

Authors

25
  • DR
    David R. SpigelCorresponding

    Sarah Cannon, Tennessee Oncology

  • CF
    Corinne Faivre-Finn

    University of Manchester, The Christie NHS Foundation Trust

  • JE
    Jhanelle E. Gray

    Moffitt Cancer Center

  • DV
    David Vicente

    Hospital Universitario Virgen Macarena

  • DP
    David Planchard

    Institut Gustave Roussy

Topics & keywords

Topics
Keywords
  • Durvalumab
  • Chemoradiotherapy
  • Lung cancer
  • Stage (stratigraphy)
  • Standard of care
  • Disease
  • Cancer
No related works found for this paper.

Funding